Profilo
Nanette Cocero currently works at PharmaJet, Inc., as Director from 2023.
Dr. Cocero also formerly worked at HilleVax, Inc., as Independent Director from 2023 to 2025 and Pfizer Vaccines LLC, as Global President from 2019 to 2022.
Dr. Cocero received her doctorate degree from the University of Pennsylvania, undergraduate degree from Cornell University, and Masters Business Admin degree from The Wharton School of the University of Pennsylvania.
Posizioni attive di Nanette Cocero
| Società | Posizione | Inizio |
|---|---|---|
PharmaJet, Inc.
PharmaJet, Inc. Medical SpecialtiesHealth Technology Operates as a medical device company which develops needle-free injection technology | Direttore/Membro del Consiglio | 11/07/2023 |
Precedenti posizioni note di Nanette Cocero
| Società | Posizione | Fine |
|---|---|---|
| HILLEVAX, INC. | Direttore/Membro del Consiglio | 17/09/2025 |
Pfizer Vaccines LLC | Presidente | 01/12/2022 |
Formazione di Nanette Cocero
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 6 |
|---|---|
PharmaJet, Inc.
PharmaJet, Inc. Medical SpecialtiesHealth Technology Operates as a medical device company which develops needle-free injection technology | Health Technology |
University of Pennsylvania
University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cornell University
Cornell University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Pfizer Vaccines LLC | |
The Wharton School of the University of Pennsylvania
The Wharton School of the University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
HilleVax, Inc.
HilleVax, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that engages in the development and commercialization of novel vaccine candidates | Health Technology |
















